Nicotinamide Supplementation Linked to 66% Reduction in Glaucoma Risk
A new study published in JAMA Ophthalmology highlights the potential benefits of nicotinamide, a form of vitamin B3, in reducing the risk of primary open-angle glaucoma (POAG) among individuals with ocular hypertension, a known risk factor for the disease. Glaucoma affects approximately 95 million people globally and can lead to irreversible vision loss. Previous research has indicated that certain nutrients, including omega-3 fatty acids and vitamins A and C, may help mitigate glaucoma risk. This study adds to the growing body of evidence regarding the protective effects of nicotinamide.
Researchers analyzed electronic medical records from 67 healthcare organizations in the United States, focusing on a cohort of about 2,900 individuals diagnosed with ocular hypertension but not yet with glaucoma. Participants were divided into two groups: one received nicotinamide supplementation while the other served as a control. Over an average follow-up period of 3.7 years, 51 individuals in the nicotinamide group were diagnosed with POAG, in contrast to 132 in the control group. This resulted in a 66% lower risk of developing glaucoma for those taking nicotinamide.
Additionally, the study reported a 43% reduction in the need for topical intraocular pressure-lowering therapies and a 62% decrease in the necessity for laser trabeculoplasty surgery among the nicotinamide group. However, it is important to note that nicotinamide is not currently an approved treatment for glaucoma. Concerns regarding the safety of high-dose nicotinamide supplementation have been raised, particularly following a joint statement from the American Glaucoma Society and the American Academy of Ophthalmology in March 2025. They cautioned that excessive intake could lead to liver damage, with ongoing clinical trials administering doses as high as 3 grams per day, while typical dosages range from 500 to 1,500 milligrams.
Potential side effects of high nicotinamide intake include gastrointestinal issues, headaches, dizziness, and more severe risks such as liver toxicity and elevated blood sugar levels. Experts emphasize the importance of consulting with healthcare providers before starting any new supplements. Dr. Benjamin Bert, an ophthalmologist not involved in the study, noted that while the findings are promising, monitoring liver function may be necessary for those taking higher doses of nicotinamide. Similarly, Dr. Ariana Levin from NYU Grossman School of Medicine highlighted the need for patients to discuss supplement use with their primary care physicians to ensure safe and effective dosages.
The study underscores the significance of early prevention strategies for glaucoma, aiming to halt or slow the progression of the disease before it causes irreversible damage. As glaucoma is a chronic condition, finding effective preventive measures is crucial. The researchers noted that further studies are needed to determine the optimal dosage of nicotinamide for protective effects against glaucoma, which could lead to more precise recommendations for its use in high-risk populations.




